156 related articles for article (PubMed ID: 9365092)
1. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica.
Dolan AL; Moniz C; Dasgupta B; Li F; Mackintosh C; Todd P; Corrigall V; Panayi GS
Arthritis Rheum; 1997 Nov; 40(11):2022-9. PubMed ID: 9365092
[TBL] [Abstract][Full Text] [Related]
2. Bone turnover in untreated polymyalgia rheumatica.
Barnes TC; Daroszewska A; Fraser WD; Bucknall RC
Rheumatology (Oxford); 2004 Apr; 43(4):486-90. PubMed ID: 14722347
[TBL] [Abstract][Full Text] [Related]
3. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica.
Dasgupta B; Dolan AL; Panayi GS; Fernandes L
Br J Rheumatol; 1998 Feb; 37(2):189-95. PubMed ID: 9569075
[TBL] [Abstract][Full Text] [Related]
4. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica.
Pearce G; Ryan PF; Delmas PD; Tabensky DA; Seeman E
Br J Rheumatol; 1998 Mar; 37(3):292-9. PubMed ID: 9566670
[TBL] [Abstract][Full Text] [Related]
5. No permanent reduction in bone mineral density during treatment of polymyalgia rheumatica and temporal arteritis using low dose corticosteroids.
Haugeberg G; Myklebust G; Dovland H; Mikkelsen B; Gran JT
Scand J Rheumatol; 2000; 29(3):163-9. PubMed ID: 10898068
[TBL] [Abstract][Full Text] [Related]
6. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort.
Krogsgaard MR; Thamsborg G; Lund B
Ann Rheum Dis; 1996 Feb; 55(2):143-6. PubMed ID: 8712867
[TBL] [Abstract][Full Text] [Related]
7. Does active treatment of rheumatoid arthritis limit disease-associated bone loss?
Dolan AL; Moniz C; Abraha H; Pitt P
Rheumatology (Oxford); 2002 Sep; 41(9):1047-51. PubMed ID: 12209040
[TBL] [Abstract][Full Text] [Related]
8. Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study.
McCarthy EM; MacMullan PA; Al-Mudhaffer S; Madigan A; Donnelly S; McCarthy CJ; Molloy ES; Kenny D; McCarthy GM
J Rheumatol; 2014 May; 41(5):931-7. PubMed ID: 24692520
[TBL] [Abstract][Full Text] [Related]
9. Polymyalgia rheumatica: inflammation suppression with low dose of methylprednisolone or modified-release prednisone.
Benucci M; Olivito B; Manfredi M; Meacci F; Infantino M; Li Gobbi F; Sarzi-Puttini P; Marcassa C; Atzeni F
Eur Rev Med Pharmacol Sci; 2015; 19(5):745-51. PubMed ID: 25807425
[TBL] [Abstract][Full Text] [Related]
10. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).
Leeb BF; Bird HA; Nesher G; Andel I; Hueber W; Logar D; Montecucco CM; Rovensky J; Sautner J; Sonnenblick M
Ann Rheum Dis; 2003 Dec; 62(12):1189-94. PubMed ID: 14644857
[TBL] [Abstract][Full Text] [Related]
11. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis.
Toussirot E; Ricard-Blum S; Dumoulin G; Cedoz JP; Wendling D
Rheumatology (Oxford); 1999 Jan; 38(1):21-7. PubMed ID: 10334678
[TBL] [Abstract][Full Text] [Related]
12. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
[TBL] [Abstract][Full Text] [Related]
13. Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.
Cutolo M; Straub RH; Foppiani L; Prete C; Pulsatelli L; Sulli A; Boiardi L; Macchioni P; Giusti M; Pizzorni C; Seriolo B; Salvarani C
J Rheumatol; 2002 Apr; 29(4):748-56. PubMed ID: 11950017
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab controls bone turnover in early polymyalgia rheumatica.
Carvajal Alegria G; Garrigues F; Bettacchioli E; Loeuille D; Saraux A; Cornec D; Devauchelle-Pensec V; Renaudineau Y
Joint Bone Spine; 2021 May; 88(3):105117. PubMed ID: 33301930
[TBL] [Abstract][Full Text] [Related]
15. Treatment of polymyalgia rheumatica with intramuscular injections of depot methylprednisolone.
Dasgupta B; Gray J; Fernandes L; Olliff C
Ann Rheum Dis; 1991 Dec; 50(12):942-5. PubMed ID: 1768166
[TBL] [Abstract][Full Text] [Related]
16. Bone mass and biochemical markers of bone turnover in children and adolescents with chronic immune thrombocytopenia: relation to corticosteroid therapy and vitamin D receptor gene polymorphisms.
Tantawy AA; El Bostany EA; Matter RM; El Ghoroury EA; Ragab S; El Sherif NH
Platelets; 2013; 24(4):282-7. PubMed ID: 22671537
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of measuring soluble interleukin-2 receptor in polymyalgia rheumatica.
Gripenberg M; Franzén P; Fröseth B
Scand J Rheumatol; 1995; 24(1):26-8. PubMed ID: 7863274
[TBL] [Abstract][Full Text] [Related]
18. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
[TBL] [Abstract][Full Text] [Related]
19. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.
van der Geest KS; Abdulahad WH; Chalan P; Rutgers A; Horst G; Huitema MG; Roffel MP; Roozendaal C; Kluin PM; Bos NA; Boots AM; Brouwer E
Arthritis Rheumatol; 2014 Jul; 66(7):1927-38. PubMed ID: 24623536
[TBL] [Abstract][Full Text] [Related]
20. Relationship of bone turnover to bone density and fractures.
Melton LJ; Khosla S; Atkinson EJ; O'Fallon WM; Riggs BL
J Bone Miner Res; 1997 Jul; 12(7):1083-91. PubMed ID: 9200008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
